Increased non‐melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single‐centre cohort study

Abstract

Compliance with skin cancer preventative measures should be highlighted to all patients with IBD. There should be a low threshold for dermatology referral for immunosuppressed patients, particularly those with a history of exposure to dual immunomodulators from a young age.